Question to the Department for Business and Trade:

To ask the Secretary of State for Business and Trade, if he will publish in full the UK-US pharmaceuticals deal, including a full assessment of the cost implications for the NHS and wider public purse.

In December 2025 we agreed a landmark deal with the US that results in 0% tariffs on pharmaceutical exports to the US for 3 years – the lowest rate offered to any country. As you’d expect, there will now be further work to finalise underpinning details.

Costs will start smaller but will increase over time as the National Institute for Health and Care Excellence (NICE) approves more life improving and lifesaving medicines. Total costs over the spending review period are expected to be around £1bn. The final costs will depend on which medicines NICE decides to approve and the actual uptake of these.